Investigational ABX464 Enhances Remission Rates, Mucosal Healing in Ulcerative Colitis Patients in Phase 2a Trial

Investigational ABX464 Enhances Remission Rates, Mucosal Healing in Ulcerative Colitis Patients in Phase 2a Trial
Abivax‘s small, anti-inflammatory molecule ABX464 significantly increased clinical remission and mucosal healing over placebo in patients with moderate to severe active ulcerative colitis resistant to other therapies, top-line results from a Phase 2a clinical trial show. “These impressive clinical trial data are indicative of the potential for ABX464’s unique mechanism of action to safely and effectively

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *